Enabling technology for therapeutics targeting membrane proteinsWe express, stabilize, select and validate membrane protein as targets CONTACT
G.CLIPS biotech created the first enabling technology to unravel the potential of drug and antibody candidates on pathology-like format membrane proteins to be used in screening efforts, characterization, structural studies, mechanism of action, pharmacological profiling and target validation.
We offer a unique technology to express, stabilize, select and validate membrane proteins as targets based on proprietary G.Screen® Platform.
We provide tailor-made services to pharma, biotech and animal health companies targeting membrane proteins (GPCRs, Receptors, Transmembrane Proteins) that would like to ascertain the necessary environment and conformation stabilization for their targets at all steps of development.
– Delivery of membrane proteins purified and stabilized in the desired conformation and specific environment for screening
– Delivery of membrane proteins purified and stabilized in the desired conformation and specific environment for immunization
– Mechanism of action and functional testing of drugs and antibody candidates on membrane protein stabilized in specific conformation(s) and environment(s)
– Target validation and profiling of drugs and antibody hits, leads and clinical candidates
PROBLEMS WE SOLVE
>> SOLUTIONS WE BRING
Antibody & Antigen Discovery
Antibody discovery and characterization
Antigens for immunization
>> NEW AND LEAD-LIKE ANTIBODY
Conformational and Environment sensitive antibody
Antibodies with improved therapeutic window
Improved binders’ ratio and vaccination success.
Pathology-oriented drug in vitro screen
Structure-based drug discovery
In vitro candidates profiling
>> LEAD-LIKE NEW CHEMICAL ENTITY
New families of biased and allosteric candidates
Improved indication selectivity
Improved new chemical entity efficacy
Non Clinical development
Toxicity due to selectivity
Pharmacology in vitro
Mechanism of action
>> De-risking & Profiling of clinical candidate
Selectivity on pathology vs non-pathology like environment
Pharmacological profiling of clinical candidate
Target characterization / validation
Ecosystem and partners
Any project ?
Any need ?